[Efficacy and safety of various doses of acetylsalicylic Acid in prevention of complications of atherothrombosis].
A L
AL
Komarov
D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D001792:Blood Platelets / Q000378:metabolism; D001808:Blood Vessels / Q000473:pathology; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D002561:Cerebrovascular Disorders / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D004305:Dose-Response Relationship, Drug; D054796:Drug Dosage Calculations; D006801:Humans; D010438:Peptic Ulcer Hemorrhage / Q000139:chemically induced*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D018570:Risk Assessment; D055502:Secondary Prevention; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000150:complications; D013927:Thrombosis / Q000097:blood / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin